

# Chapter 139

## Hereditary Disorders of Genome Instability and DNA Repair

Thomas M. Runger, John J. DiGiovanna,  
& Kenneth H. Kraemer

### REFERENCES

1. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. *Nature* **411**:366, 2001 [PMID: 11357144]
2. Mohrenweiser HW, Wilson DM III, Jones IM: Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. *Mutat Res* **526**:93, 2003 [PMID: 12714187]
3. Bielas JH, Loeb LA: Quantification of random genomic mutations. *Nat Methods* **2**:285, 2005 [PMID: 15782221]
4. Loeb LA: Cancer cells exhibit a mutator phenotype. *Adv Cancer Res* **72**:25, 1998 [PMID: 9338073]
5. Renwick A et al: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. *Nat Genet* **38**:873, 2006 [PMID: 16832357]
6. Su Y, Swift M: Mortality rates among carriers of ataxia-telangiectasia mutant alleles. *Ann Intern Med* **133**:770, 2000 [PMID: 11085839]
7. Hickson ID: RecQ helicases: Caretakers of the genome. *Nat Rev Cancer* **3**:169, 2003 [PMID: 12612652]
8. Opresko PL, Cheng WH, Bohr VA: Junction of RecQ helicase biochemistry and human disease. *J Biol Chem* **279**:18099, 2004 [PMID: 15023996]
9. Harrigan JA, Bohr VA: Human diseases deficient in RecQ helicases. *Biochimie* **85**:1185, 2003 [PMID: 14726023]
10. Aubert G, Lansdorp PM: Telomeres and aging. *Physiol Rev* **88**:557–579, 2008
11. Savage SA, Blanche PB: Dyskeratosis congenita. *Hematol Oncol Clin North Am* **23**:215–231, 2009
12. Wang Y et al: BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. *Genes Dev* **14**:927, 2000 [PMID: 10783165]
13. Bootsma D et al: Nucleotide excision repair syndromes: Xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. In: *The Genetic Basis of Human Cancer*, 2nd edition, edited by B Vogelstein, KW Kinzler. New York: McGraw-Hill, 2002, p. 211
14. Kraemer KH, Lee MM, Scotto J: Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. *Arch Dermatol* **123**:241, 1987 [PMID: 3545087]
15. Kleijer WJ et al: Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. *DNA Repair (Amst)* **7** (5):744–750, 2008
16. Hirai Y et al: Heterozygous individuals bearing a founder mutation in the XPA DNA repair gene comprise nearly 1% of the Japanese population. *Mutat Res* **601**:171–178, 2006
17. Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, Oh KS, Imoto K, Inui H, Moriwaki SI, Emmert S, Pike KM, Raziuddin A, Plona TM, DiGiovanna JJ, Tucker MA, Kraemer KH: Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair. *J Medical Genetics* **48**:168–176, 2011
18. Kraemer KH et al: Xeroderma pigmentosum and related disorders: Examining the linkage between defective DNA repair and cancer. *J Invest Dermatol* **103**:96S, 1994
19. Ramkumar HL, Brooks BP, Cao X, Tamura D, DiGiovanna JJ, Kraemer KH, Chan CC: Ophthalmic manifestations and histopathology of xeroderma pigmentosum: two clinicopathological cases and review of the literature. *Survey of Ophthalmology* **56**:348–361, 2011
20. Rapin I et al: Cockayne syndrome and xeroderma pigmentosum. *Neurology* **55**:1442, 2000 [PMID: 11185579]
21. Bellows RA et al: Ocular manifestations of xeroderma pigmentosum in a black family. *Arch Ophthalmol* **92**:113, 1974 [PMID: 4847501]
22. Kraemer KH: Sunlight and skin cancer: Another link revealed. *Proc Natl Acad Sci USA* **94**:11, 1997 [PMID: 8990152]

23. Mamada A, Kondo S, Satoh Y: Different sensitivities to ultraviolet light-induced cytotoxicity and sister chromatid exchanges in xeroderma pigmentosum and Bloom's syndrome fibroblasts. *Photodermatol* **6**:124, 1989 [PMID: 2762203]
24. Cleaver JE: Defective repair replication of DNA in xeroderma pigmentosum. *Nature* **218**:652, 1968 [PMID: 5655953]
25. Arlett CF et al: Minimal ionizing radiation sensitivity in a large cohort of xeroderma pigmentosum fibroblasts. *Br J Radiol* **81**(961):51-58, 2008
26. Wood RD et al: Human DNA repair genes. *Science* **291**:1284, 2001 [PMID: 11181991]
27. Johnson RE et al: hRAD30 mutations in the variant form of xeroderma pigmentosum. *Science* **285**:263, 1999 [PMID: 10398605]
28. Masutani C et al: The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. *Nature* **399**:700, 1999 [PMID: 10385124]
29. Ramsay CA et al: Prenatal diagnosis of xeroderma pigmentosum. Report of the first successful case. *Lancet* **2**:1109, 1974 [PMID: 4139407]
30. Kore-eda S et al: A case of xeroderma pigmentosum group A diagnosed with a polymerase chain reaction (PCR) technique. Usefulness of PCR in the detection of point mutation in a patient with a hereditary disease. *Arch Dermatol* **128**:971, 1992 [PMID: 1352672]
31. Kleijer WJ, van der Sterre ML, Garritsen VH, Raams A, Jaspers NG: Prenatal diagnosis of xeroderma pigmentosum and trichothiodystrophy in 76 pregnancies at risk. *Prenat Diagn* **27**(12):1133-1137, 2007
32. Yang Y, Ding B, Wang K, Bu D, Tu P, Zhu X: DNA-based prenatal diagnosis in a Chinese family with xeroderma pigmentosum group A. *Br J Dermatol* **150**(6):1190-1193, 2004
33. Furuta T et al: Transcription coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. *Cancer Res* **62**:4899, 2002 [PMID: 12208738]
34. Agrawal K et al: Xeroderma pigmentosum: Resurfacing versus dermabrasion. *Br J Plast Surg* **45**:311, 1992 [PMID: 1623349]
35. Atabay K et al: Facial resurfacing in xeroderma pigmentosum with monoblock full-thickness skin graft. *Plast Reconstr Surg* **87**:1121, 1991 [PMID: 2034733]
36. Konig A et al: Dermabrasion for the treatment of xeroderma pigmentosum. *Arch Dermatol* **134**:241, 1998 [PMID: 9487222]
37. Leal-Khoury S et al: Management of a young patient with xeroderma pigmentosum. *Pediatr Dermatol* **11**:72, 1994 [PMID: 8170856]
38. Tamura D, DiGiovanna JJ, Kraemer KH: Xeroderma pigmentosum. In: *Treatment of Skin Disease – Comprehensive Therapeutic Strategies*, 3rd edition, edited by Mark G. Lebwohl, Warren R. Heymann, John Berth-Jones, Ian Coulson. London, Saunders, Elsevier, 2010, pp. 789-792
39. Kraemer KH et al: The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: The xeroderma pigmentosum paradigm. *Arch Dermatol* **130**:1018, 1994 [PMID: 8053698]
40. DiGiovanna JJ et al: Xeroderma pigmentosum: Spinal cord astrocytoma with 9-year survival after radiation and isotretinoin therapy. *J Cutan Med Surg* **2**:153, 1998 [PMID: 9479081]
41. Arlett CF et al: Studies of a new case of xeroderma pigmentosum (XP3BR) from complementation group G with cellular sensitivity to ionizing radiation. *Carcinogenesis* **1**:745, 1980 [PMID: 11219864]
42. Arlett CF et al: Clinical and cellular ionizing radiation sensitivity in a patient with xeroderma pigmentosum. *Br J Radiol* **79**:510, 2006 [PMID: 16714754]
43. Kraemer KH et al: Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. *N Engl J Med* **318**:1633, 1988 [PMID: 3287161]
44. Yarosh D et al: Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study. Xeroderma Pigmentosum Study Group. *Lancet* **357**:926, 2001 [PMID: 11289350]
45. Turner MLC et al: Clearing of melanoma in situ with intralesional interferon alfa in a patient with xeroderma pigmentosum. *Arch Dermatol* **130**:1491, 1994 [PMID: 7986121]
46. Giannotti B et al: The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin. *Clin Exp Dermatol* **28**:33, 2003 [PMID: 14616811]
47. Nagore E et al: Excellent response of basal cell carcinomas and pigimentary changes in xeroderma pigmentosum to imiquimod 5% cream. *Br J Dermatol* **149**:858, 2003 [PMID: 14616381]
48. Nijsten T, Lapiere K, Lambert J: A patient with xeroderma pigmentosum treated with imiquimod 5% cream. *J Am Acad Dermatol* **52**:170, 2005 [PMID: 15627108]

49. Weisberg NK, Varghese M: Therapeutic response of a brother and sister with xeroderma pigmentosum to imiquimod 5% cream. *Dermatol Surg* **28**:518, 2002 [PMID: 12081683]
50. Jalali S et al: Penetrating keratoplasty in xeroderma pigmentosum. Case reports and review of the literature. *Cornea* **13**:527, 1994 [PMID: 7842713]
51. Calonge M et al: Management of corneal complications in xeroderma pigmentosum. *Cornea* **11**:173, 1992 [PMID: 1582221]
52. Gaasterland DE, Rodrigues MM, Moshell AN: Ocular involvement in xeroderma pigmentosum. *Ophthalmology* **89**:980, 1982 [PMID: 7133643]
53. Nishigori C et al: Gene alterations and clinical characteristics of xeroderma pigmentosum group A patients in Japan. *Arch Dermatol* **130**:191, 1994 [PMID: 7905727]
54. Oh KS et al: Phenotypic heterogeneity in the XPB DNA helicase gene (ERCC3): Xeroderma pigmentosum without and with Cockayne syndrome. *Hum Mutat* **27**:1092, 2006 [PMID: 16947863]
55. Chavanne F et al: Mutations in the XPC gene in families with xeroderma pigmentosum and consequences at the cell, protein, and transcript levels. *Cancer Res* **60**:1974, 2000 [PMID: 10766188]
56. Gozukara EM et al: A stop codon in xeroderma pigmentosum group C families in Turkey and Italy: Molecular genetic evidence for a common ancestor. *J Invest Dermatol* **117**:197, 2001 [PMID: 11511294]
57. Khan SG et al: Xeroderma pigmentosum group C splice mutation associated with autism and hypoglycinemia. *J Invest Dermatol* **111**:791, 1998 [PMID: 9804340]
58. Khan SG et al: Two essential splice lariat branch-point sequences in one intron in a xeroderma pigmentosum DNA repair gene: Mutations result in reduced XPC mRNA levels that correlate with cancer risk. *Hum Mol Genet* **13**:343, 2004 [PMID: 14662655]
59. Khan SG et al: Reduced XPC DNA repair gene mRNA levels in clinically normal parents of xeroderma pigmentosum patients. *Carcinogenesis* **27**:84, 2006 [PMID: 16081512]
60. Slor H et al: Clinical, cellular, and molecular features of an Israeli xeroderma pigmentosum family with a frameshift mutation in the XPC gene: Sun protection prolongs life. *J Invest Dermatol* **115**:974, 2000 [PMID: 11121128]
61. Khan SG, Oh KS, Emmert S, Imoto K, Tamura D, DiGiovanna JJ, Shahlavi T, Armstrong N, Baker CC, Neuburg M, Zalewski C, Brewer C, Wiggs E, Schiffmann R, Kraemer KH: XPC Initiation codon mutation in xeroderma pigmentosum patients with and without neurological symptoms. *DNA Repair* **8**:114-125, 2009
62. Lehmann AR: The xeroderma pigmentosum group D (XPD) gene: One gene, two functions, three diseases. *Genes Dev* **15**:15, 2001 [PMID: 11156600]
63. Broughton BC et al: Two individuals with features of both xeroderma pigmentosum and trichothiodystrophy highlight the complexity of the clinical outcomes of mutations in the XPD gene. *Hum Mol Genet* **10**:2539, 2001 [PMID: 11709541]
64. Graham JM Jr et al: Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy. *Am J Hum Genet* **69**:291, 2001 [PMID: 11443545]
65. Itoh T et al: Reinvestigation of the classification of five cell strains of xeroderma pigmentosum group E with reclassification of three of them. *J Invest Dermatol* **114**:1022, 2000 [PMID: 10771487]
66. Oh KS, Emmert S, Tamura D, DiGiovanna JJ, Kraemer KH: Multiple skin cancers in adults with mutations in the XP-E (DDB-2) DNA repair gene. *J Invest Dermatol* **131**:785-788, 2011
67. Matsumura Y et al: Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. *Hum Mol Genet* **7**:969, 1998 [PMID: 9580660]
68. Sijbers AM et al: Homozygous R788W point mutation in the XPF gene of a patient with xeroderma pigmentosum and late-onset neurologic disease. *J Invest Dermatol* **110**:832, 1998 [PMID: 9579555]
69. Emmert S et al: Relationship of neurologic degeneration to genotype in three xeroderma pigmentosum group G patients. *J Invest Dermatol* **118**:972, 2002 [PMID: 12060391]
70. Broughton BC et al: Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients. *Proc Natl Acad Sci U S A* **99**:815, 2002 [PMID: 11773631]
71. Inui H, Oh KS, Nadem C, Ueda T, Khan SG, Metin A, Gozukara E, Emmert S, Slor H, Busch D, Baker CC, DiGiovanna JJ, Tamura D, Seitz CS, Gratchev A, Wu WH, Chung KY, Chung HJ, Azizi E, Woodgate R, Schneider TD, Kraemer KH: Xeroderma pigmentosum variant patients from America, Europe and Asia. *J Invest. Dermatol* **128**:2055-2068, 2008
72. Swift M, Chase C: Cancer in families with xeroderma pigmentosum. *J Natl Cancer Inst* **62**:1415, 1979 [PMID: 286113]

73. Cantani A et al: Rare syndromes. I. Cockayne syndrome: A review of the 129 cases so far reported in the literature. *Riv Eur Sci Med Farmacol* **9**:9, 1987 [PMID: 3334173]
74. Özdirim E et al: Cockayne syndrome: Review of 25 cases. *Pediatr Neurol* **15**:312, 1996
75. Nance MA, Berry SA: Cockayne syndrome: Review of 140 cases. *Am J Med Genet* **42**:68, 1992 [PMID: 1308368]
76. Cockayne EA: Dwarfism with retinal atrophy and deafness. *Arch Dis Child* **11**:1, 1936
77. Traboulsi EI, De Becker I, Maumenee IH: Ocular findings in Cockayne syndrome. *Am J Ophthalmol* **114**:579, 1992 [PMID: 1443019]
78. Jaeken J et al: Clinical and biochemical studies in three patients with severe early infantile Cockayne syndrome. *Hum Genet* **83**:339, 1989 [PMID: 2478446]
79. Patton MA et al: Early onset Cockayne syndrome: Case reports with neuropathological and fibroblast studies. *J Med Genet* **26**:154, 1989 [PMID: 2468771]
80. Meira LB et al: Manitoba aboriginal kindred with original cerebro-oculo-facio-skeletal syndrome has a mutation in the cockayne syndrome group B (CSB) gene. *Am J Hum Genet* **66**:1221, 2000 [PMID: 10739753]
81. Del Bigio MR et al: Neuropathological findings in eight children with cerebro-oculo-facio-skeletal (COFS) syndrome. *J Neuropathol Exp Neurol* **56**:1147, 1997
82. Talwar D, Smith SA: CAMFAK syndrome: A demyelinating inherited disease similar to Cockayne syndrome. *Am J Med Genet* **34**:194, 1989 [PMID: 2554729]
83. Brumback RA et al: Normal pressure hydrocephalus. Recognition and relationship to neurological abnormalities in Cockayne syndrome. *Arch Neurol* **35**:337, 1978 [PMID: 655905]
84. Cleaver JE et al: A summary of mutations in the UV-sensitive disorders: Xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. *Hum Mutat* **14**:9, 1999 [PMID: 10447254]
85. Laugel V et al: Mutation update for the CSB/ERCC6 and CSA/ERCC8 genes involved in Cockayne syndrome. *Hum Mutat* **31** (2):113-126, 2010
86. Lehmann AR, Francis AJ, Giannelli F: Prenatal diagnosis of Cockayne's syndrome. *Lancet* **1**:486, 1985 [PMID: 2579301]
87. Itin PH, Sarasin A, Pittelkow MR: Trichothiodystrophy: Update on the sulfur-deficient brittle hair syndromes. *J Am Acad Dermatol* **44**:891, 2001 [PMID: 11369901]
88. Liang C et al: Characterization of tiger tail banding and hair shaft abnormalities in trichothiodystrophy. *J Am Acad Dermatol* **52**:224, 2005 [PMID: 15692466]
89. Liang C et al: Structural and molecular hair abnormalities in trichothiodystrophy. *J Invest Dermatol* **126**:2210, 2006 [PMID: 16728971]
90. Price VH et al: Trichothiodystrophy: Sulfur-deficient brittle hair as a marker for a neuroectodermal symptom complex. *Arch Dermatol* **116**:1375, 1980 [PMID: 7458366]
91. Schlucker S et al: Conformational differences in protein disulfide linkages between normal hair and hair from subjects with trichothiodystrophy: A quantitative analysis by Raman microspectroscopy. *Biopolymers* **82**:615, 2006 [PMID: 16557500]
92. Tay CH: Ichthyosiform erythroderma, hair shaft abnormalities, and mental and growth retardation. A new recessive disorder. *Arch Dermatol* **104**:4, 1971 [PMID: 5120162]
93. Brooks BP, Thompson AH, Clayton JA, Chan CC, Tamura D, Zein WM, Blain D, Hadsall C, Rowan J, Bowles KE, DiGiovanna JJ, Kraemer KH: The Ocular Manifestations of Trichothiodystrophy. *Ophthalmology* (In Press)
94. Faghri S et al: Trichothiodystrophy: A systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. *J Med Genet* **45**(10):609-621, 2008
95. Zhou X et al: Brittle hair, developmental delay, neurologic abnormalities and photosensitivity in a 4 year old girl. *J Am Acad of Dermatol* **63**:323-328, 2010
96. Ostergaard JR, Christensen T: The central nervous system in Tay syndrome. *Neuropediatrics* **27**:326, 1996 [PMID: 9050052]
97. Baden HP, Jackson CE, Weiss L, Jimbow K, Lee L, Kubilis J, Gold RJM: The physicochemical properties of hair in the BIDS syndrome. *Am J Hum Genet* **28**:514-521, 1976
98. Nakabayashi K et al: Identification of C7orf11 (TTDN1) gene mutations and genetic heterogeneity in nonphotosensitive trichothiodystrophy. *Am J Hum Genet* **76**:510, 2005 [PMID: 15645389]
99. Dubaele S et al: Basal transcription defect discriminates between xeroderma pigmentosum and trichothiodystrophy in XPD patients. *Mol Cell* **11**:1635, 2003 [PMID: 12820975]

100. Moslehi R, Signore C, Tamura D, Mills JL, Di-Giovanna JJ, Tucker MA, Troendle J, Ueda T, Boyle J, Khan SG, Oh KS, Goldstein AM, Kraemer KH: Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development. *Clinical Genetics* **77**:365-373, 2010
101. Tamura D, Merideth M, DiGiovanna JJ, Zhou X, Tucker MA, Goldstein AM, Brooks BP, Khan SG, Oh KS, Ueda T, Boyle J, Moslehi R, Kraemer KH: High risk pregnancy and neonatal complications in the DNA repair and transcription disorder trichothiodystrophy: Report of 27 affected pregnancies. *Prenatal Diagnosis* 2011 Doi:10.1002/pd.2829
102. Brooks BP, Thompson AH, Clayton JA, Chan CC, Tamura D, Zein WM, Blain D, Hadsall C, Rowan J, Bowles KS, DiGiovanna JJ, Kraemer KH: The ocular manifestations of trichothiodystrophy. *Ophthalmology* (In Press)
103. Moslehi R et al: Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development. *Clin Genet* **77**(4):365-373, 2010
104. German J: Bloom's syndrome. 20. The first 100 cancers. *Cancer Genet Cytogenet* **93**:100, 1997 [PMID: 9062585]
105. Shahrabani-Gargir L et al: High frequency of a common Bloom syndrome Ashkenazi mutation among Jews of Polish origin. *Genet Test* **2**:293, 1998 [PMID: 10464606]
106. Thompson LH, Schild D: Recombinational DNA repair and human disease. *Mutat Res* **509**:49, 2002 [PMID: 12427531]
107. Singh DK, Ahn B, Bohr VA: Roles of RECQ helicases in recombination based DNA repair, genomic stability and aging. *Biogerontology* **10**:235-252, 2009
108. Chaganti RS, Schonberg S, German J: A manifold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. *Proc Natl Acad Sci USA* **71**:4508, 1974 [PMID: 4140506]
109. Peleg L et al: Bloom syndrome and Fanconi's anemia: Rate and ethnic origin of mutation carriers in Israel. *Isr Med Assoc J* **4**:95, 2002 [PMID: 11876000]
110. Ishikawa Y et al: Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. *Cancer* **85**:1345, 1999 [PMID: 10189141]
111. Epstein CE et al: Werner syndrome. A Review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. *Medicine* **45**:177, 1966 [PMID: 5327241]
112. Ruprecht KW: Ophthalmological aspects in patients with Werner's syndrome. *Arch Gerontol Geriatrics* **9**:263, 1989 [PMID: 2640084]
113. Goto M et al: Excess of rare cancers in Werner syndrome (adult progeria). *Cancer Epidemiol Biomark Prev* **5**:239, 1996 [PMID: 8722214]
114. Chen L et al: WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair. *Aging Cell* **2**:191, 2003 [PMID: 12934712]
115. Opresko PL et al: Werner syndrome and the function of the Werner protein; what they can teach us about the molecular aging process. *Carcinogenesis* **24**:791, 2003 [PMID: 12771022]
116. Morita K et al: Werner's syndrome—Chromosome analyses of cultured fibroblasts and mitogen-stimulated lymphocytes. *Br J Dermatol* **136**:620, 1997 [PMID: 9155973]
117. Wang LL et al: Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. *Am J Med Genet* **102**:11, 2001 [PMID: 11471165]
118. Larizza L, Roversi G, Volpi L: Rothmund-Thomson syndrome. *Orphanet J Rare Dis* **5**:2, 2010
119. Kitao S et al: Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. *Nature Genet* **22**:82, 1999 [PMID: 10319867]
120. Kerr B et al: Rothmund-Thomson syndrome: Two case reports show heterogeneous cutaneous abnormalities, an association with genetically programmed ageing changes, and increased chromosomal radiosensitivity. *J Med Genet* **33**:928, 1996 [PMID: 8950673]
121. Smith PJ et al: Enhanced radiosensitivity and defective DNA repair in cultured fibroblasts derived from Rothmund Thomson syndrome patients. *Mutat Res* **94**:213, 1982 [PMID: 7099192]
122. Grant SG et al: Analysis of genomic instability using multiple assays in a patient with Rothmund-Thomson syndrome. *Clin Genet* **58**:209, 2000 [PMID: 11076043]
123. Yin J et al: RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes, interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway. *Hum Mol Genet* **13**:2421, 2004 [PMID: 15317757]
124. Shinya A et al: A case of Rothmund-Thomson syndrome with reduced DNA repair capacity. *Arch Dermatol* **129**:332, 1993 [PMID: 8447670]
125. Marin-Bertolin S et al: Squamous cell carcinoma of the tongue in a patient with Rothmund-Thomson syndrome. *Br J Plast Surg* **51**:646, 1998 [PMID: 10209473]

126. Auerbach AD: Fanconi anemia. *Dermatol Clin* 13:41, 1995 [PMID: 7712649]
127. Kutler DI et al: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). *Blood* 101:1249, 2003 [PMID: 12393516]
128. Braun M et al: Thrombocytopenia, multiple mucosal squamous cell carcinomas, and dyspigmentation. *J Am Acad Dermatol* 54:1056, 2006 [PMID: 16713462]
129. Shimamura A, Alter BP: Pathophysiology and management of inherited bone marrow failure syndromes. *Blood Reviews* 24:101-122, 2010
130. De Kerviler E et al: The clinical and radiological features of Fanconi's anaemia. *Clin Radiol* 55:340, 2000
131. Gmyrek D, Syllm-Rapoport I: Fanconi's anemia: Analysis of 129 described cases. *Z Kinderheilkd* 91:294, 1964
132. Alter BP et al: Cancer in Fanconi anemia. *Blood* 101:2072, 2003 [PMID: 12584146]
133. Alter BP: Cancer in Fanconi anemia, 1927–2001. *Cancer* 97:425, 2003 [PMID: 12518367]
134. Auerbach AD, Allen RG: Leukemia and preleukemia in Fanconi anemia patients. A review of the literature and report of the International Fanconi Anemia Registry. *Cancer Genet Cytogenet* 51:1, 1991 [PMID: 1984836]
135. Rosenberg PS, Greene MH, Alter BP: Cancer incidence in persons with Fanconi anemia. *Blood* 101:822, 2003 [PMID: 12393424]
136. Bogliolo M et al: The Fanconi anaemia genome stability and tumour suppressor network. *Mutagenesis* 17:529, 2002 [PMID: 12435850]
137. D'Andrea AD, Grompe M: The Fanconi anemia/BRCA pathway. *Nat Rev Cancer* 3:23, 2003 [PMID: 12509764]
138. Garcia-Higuera I et al: Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. *Mol Cell* 7:249, 2001 [PMID: 11239454]
139. Taniguchi T et al: Convergence of the Fanconi anemia and ataxia telangiectasia signaling pathways. *Cell* 109:459, 2002 [PMID: 12086603]
140. Dunn J et al: Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar UV. *Cancer Res* 66:1140, 2006
141. Howlett NG et al: The Fanconi anemia pathway is required for the DNA replication stress response and for the regulation of common fragile site stability. *Hum Mol Genet* 14:693, 2005 [PMID: 15661754]
142. Lomonosov M et al: Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. *Genes Dev* 17:3017, 2003 [PMID: 14681210]
143. Osborn AJ, Elledge SJ, Zou L: Checking on the fork: The DNA-replication stress-response pathway. *Trends Cell Biol* 12:509, 2002 [PMID: 12446112]
144. Thompson LH et al: How Fanconi anemia proteins promote the four Rs: Replication, recombination, repair, and recovery. *Environ Mol Mutagen* 45:128, 2005 [PMID: 15668941]
145. Joenje H, Patel KJ: The emerging genetic and molecular basis of Fanconi anaemia. *Nat Rev Genet* 2:446, 2001 [PMID: 11389461]
146. Taniguchi T, Dandrea AD: Molecular pathogenesis of Fanconi anemia. *Int J Hematol* 75:123, 2002 [PMID: 11939257]
147. Wang W: Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. *Nature Rev Genet* 8:735-748, 2007
148. Vulliamy TJ et al: Mutations in dyskeratosis congenita: Their impact on telomere length and the diversity of clinical presentation. *Blood* 107:2680, 2006 [PMID: 16332973]
149. Alter BP et al: Rosenberg. Cancer in dyskeratosis congenita. *Blood* 113(26):6549-6557, 2009
150. Sirinavin C, Trowbridge AA: Dyskeratosis congenita: Clinical features and genetic aspects. Report of a family and review of the literature. *J Med Genet* 12:339, 1975 [PMID: 768476]
151. Knight S et al: Dyskeratosis Congenita (DC) Registry: Identification of new features of DC. *Br J Haematol* 103:990, 1998 [PMID: 9886310]
152. Dokal I: Dyskeratosis congenita in all its forms. *Br J Haematol* 110:768, 2000 [PMID: 11054058]
153. Kelly TE, Stelling CB: Dyskeratosis congenita: Radiologic features. *Pediatr Radiol* 12:31, 1982 [PMID: 6174925]
154. Mills SE et al: Intracranial calcifications and dyskeratosis congenita. *Arch Dermatol* 115:1437, 1979 [PMID: 533291]
155. Connor JM, Teague RH: Dyskeratosis congenita. Report of a large kindred. *Br J Dermatol* 105:321, 1981 [PMID: 7272212]
156. Ghavamzadeh A et al: Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. *Bone Marrow Transplant* 23:299, 1999 [PMID: 10084264]

157. Dokal I et al: Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements. *Blood* **80**:3090, 1992 [PMID: 1361371]
158. Hassock S, Vetrie D, Giannelli F: Mapping and characterization of the X-linked dyskeratosis congenita (DKC) gene. *Genomics* **55**:21, 1999 [PMID: 9888995]
159. Mitchell JR, Wood E, Collins K: A telomerase component is defective in the human disease dyskeratosis congenita. *Nature* **402**:551, 1999 [PMID: 10591218]
160. Marciniak RA, Johnson FB, Guarente L: Dyskeratosis congenita, telomeres and human ageing. *Trends Genet* **16**:193, 2000 [PMID: 10782108]
161. Vulliamy TJ et al: Very short telomeres in the peripheral blood of patients with X-linked and autosomal dyskeratosis congenita. *Blood Cells Mol Dis* **27**:353, 2001 [PMID: 11259155]
162. Dokal I: Dyskeratosis congenita. A disease of premature ageing. *Lancet* **358**:S27, 2001
163. Collins K, Mitchell JR: Telomerase in the human organism. *Oncogene* **21**:564, 2002 [PMID: 11850781]
164. Heiss NS et al: X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. *Nature Genet* **19**:32, 1998 [PMID: 9590285]
165. Knight SW et al: X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. *Am J Hum Genet* **65**:50, 1999 [PMID: 10364516]
166. Vulliamy TJ et al: Dyskeratosis congenita caused by a 3' deletion: Germline and somatic mosaicism in a female carrier. *Blood* **94**:1254, 1999 [PMID: 10438713]
167. Elliott AM et al: Dyskeratosis congenita: An autosomal recessive variant. *Am J Med Genet* **83**:178, 1999 [PMID: 10096592]
168. Vulliamy T et al: The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. *Nature* **413**:432, 2001 [PMID: 11574891]

